Neuroendocrine Neoplasms of the Pancreas Bookmark

Curated by Editor in Chief George Lundberg, MD:

The pancreas is made up of three main cellular components: glands, ducts, and hormone-producing cells, some of which are known as neuroendocrine cells. All can develop malignant tumors, with very different characteristics.

To learn more about pancreatic neuroendocrine tumors, which begin in neuroendocrine cells in the pancreas, check out this comprehensive, authoritative, detailed, up-to-date, unbiased overview from Medscape. (Free registration may be required to view the content.)

All About Pancreatic Cancer, for Patients and Caregivers Bookmark

Curated by Editor in Chief George Lundberg, MD:

The National Cancer Institute has put together this useful guide to pancreatic cancer for patients and caregivers. (Click here for a different version for health professionals.)

All About Pancreatic Cancer, for Cancer Professionals Bookmark

Curated by Editor in Chief George Lundberg, MD:

The National Cancer Institute has put together this useful guide to pancreatic cancer, aimed for an audience of oncology professionals. (Click here for the patient-oriented version.)

Prime Source for Information About Pancreatic Cancer Bookmark

Curated by Editor in Chief George Lundberg, MD:

Founded in 1999, the Pancreatic Cancer Action Network (PanCAN) provides much useful information for patients and caregivers dealing with this disease.

Adenocarcinoma of the Pancreas Bookmark

Curated by Editor in Chief George Lundberg, MD:

“Pancreatic cancer is the tenth most common cancer in men and the ninth most common in women, but it is the fourth leading cause of cancer deaths, being responsible for 7% of all cancer-related deaths in men and 8% in women.”

To learn more about pancreatic cancer, check out this comprehensive, credible, authoritative, up-to-date description and discussion from Medscape. (Free registration may be required to view the content.)

Long-Term Survival in Glioblastoma Bookmark

Curated by Editor in Chief George Lundberg, MD:

When overall clinical trial results are presented as “medians,” obviously, the same number of patients lived longer as did those who lived less long than the median. It can be useful to study the “tail” of the long survivors for clues of combinations of treatments that  may help others. A July 2019 Journal of Neuro-Oncology paper explores this topic.

Patients with Newly Diagnosed Brain Tumors Bookmark

Curated by Editor in Chief George Lundberg, MD:

Receiving a brain tumor diagnosis can be shocking for patients and their families. The Musella Foundation’s free “Brain Tumor Guide for the Newly Diagnosed” provides up-to-date guidance for people in this difficult position.

.

Brainstem Gliomas Bookmark

Curated by Editor in Chief George Lundberg, MD:

A brainstem glioma is a very serious disease that is rare and mostly affects children. Diffuse pontine intrinsic glioma  (DPIG) is one type of brainstem glioma. For an authoritative, up-to-date, detailed, comprehensive, and unbiased overview of brainstem gliomas, check out this presentation and discussion. (You may be required to register for free to view it.)

Glioblastoma Multiforme (GBM) Bookmark

Curated by Editor in Chief George Lundberg, MD:

Most malignant brain tumors are gliomas, which begin in nerve-supporting cells known as glial cells. “Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors,” according to this comprehensive presentation about GBM. Check it out for an authoritative, up-to-date, detailed, unbiased perspective. (You may be required to register for free to view the presentation.)

Nuclear Medicine Therapy Shows Long-Term Effectiveness for Malignant Neuroendocrine Tumors Bookmark

Excerpt from the Society of Nuclear Medicine and Molecular Imaging:

“A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study is featured in the April issue of The Journal of Nuclear Medicine.

“While PRRT has been used for more than 20 years to treat patients with inoperable or metastatic somatostatin receptor–positive tumors, knowledge of long-term outcomes has been limited. A number of clinical studies have demonstrated PRRT’s efficacy, and the overall response rate (including complete response, partial response, minor response, and stable disease) is about 70-80 percent for the two most commonly used radiopharmaceuticals: yttrium-90 (⁹⁰Y)-DOTATOC (best suited for treating larger tumors) and lutetium-177 (¹⁷⁷Lu)-DOTATATE (preferred for smaller tumors). For patients who respond to PRRT, the prognosis is generally favorable, with a median time to disease progression of three to four years.”

Go to full article published by the Society of Nuclear Medicine and Molecular Imaging on April 26, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.